-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 4, Herui Gene officially announced the completion of the B1 round of financing
Herui Gene was established in August 2017.
According to statistics, in 2020, a total of 16 companies with a clear early screening business layout completed 17 financings, with a cumulative financing amount of approximately 6.
Herui Gene's PreCar liver cancer early screening project with a total investment of more than 200 million yuan is the first and only prospective cohort research project of ultra-large-scale liver cancer early screening based on NGS technology in China.
On June 22, 2021, the country’s first "Expert Consensus on Early Liver Cancer Screening Strategies in China" was officially released.
In addition, the company’s liver cancer early screening product "Laisining" relies on the national 13th Five-Year Plan of major scientific research projects.
In response to the success of this financing, Herui Gene CEO Zhou Jun said: "Herui Gene will continue to adhere to the mission of'achieve early diagnosis and treatment of all tumors, and obtain precise treatment for all patients'.